Clinical Trials
58 trialsEfficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
National Cancer Institute (NCI)
METALLICA
MedSIR
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
The XENERAâ„¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Boehringer Ingelheim
ASPIRE
Emory University
POLLY
Dartmouth-Hitchcock Medical Center
ARB
Queen Mary University of London
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Abramson Cancer Center at Penn Medicine
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
TP-II
Palleos Healthcare GmbH
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
BOLERO-5
Novartis
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
NeoTEE
First Affiliated Hospital, Sun Yat-Sen University
PEARL
Jules Bordet Institute
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
National Cancer Institute (NCI)
AMICA
GBG Forschungs GmbH
Exemestane in Post-Menopausal Women With NSCLC
Masonic Cancer Center, University of Minnesota
BOLERO-4
Novartis
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Spanish Breast Cancer Research Group
INGE-B
iOMEDICO AG
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Calithera Biosciences, Inc
SEAT
Shanghai Jiao Tong University School of Medicine
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
ENCORE301
Syndax Pharmaceuticals
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
University of Colorado, Denver
BOLERO-6
Novartis
GIADA
Istituto Oncologico Veneto IRCCS
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
City of Hope Medical Center
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
NYU Langone Health
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
University of Alabama at Birmingham
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
MK-8669-064
Merck Sharp & Dohme LLC
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Ohio State University Comprehensive Cancer Center
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
TREnd
Fondazione Sandro Pitigliani
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Merck Sharp & Dohme LLC
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Emory University
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
Fudan University
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Novartis
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Georgetown University
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Merrimack Pharmaceuticals
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
NYU Langone Health
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
Biogen